8 completed, 2 unknown, 1 active not recruiting, 1 no longer available. 4 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 4 | Active not recruiting 1, Completed 1, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
Follow this drug Literature Review of Rose Bengal trials Research Report on Rose Bengal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II Difluprednate Ophthalmic, Rose Bengal, Moxifloxacin Ophthalmic - Bacterial Keratitis | Phase 3 | Active not recruiting | University of California, San Francisco | 60 | 2024-07-01 | 2026-08-17 |
| Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction Moxifloxacin Ophthalmic, Chlorhexidine Gluconate, Natamycin - Acanthamoeba Keratitis, Fungal Keratitis | Phase 3 | Completed | University of California, San Francisco | 330 | 2022-08-03 | 2026-09-03 |
| Curcumin; Rose Bengal; Denture Stomatitis Curcumin, Rose Bengal, Nystatin - Candida Albicans Infection, Cigarette Smoking | Phase 3 | Unknown | King Saud University | 45 | 2018-07-03 | 2021-04-08 |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec - Cutaneous Melanoma | Phase 3 | Terminated | Provectus Biopharmaceuticals, Inc. | 20 | 2015-04-01 | 2022-01-19 |
| Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy Biopsy, Rose Bengal, toluidine blue - Oral Leukoplakia, Oral Lichen Planus | Completed | The Oxford Dental College, Hospital and Research Center, Bangalore, India | 27 | 2015-03-01 | 2018-11-05 | |
| A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10 Topical Rose Bengal, 0.005% - Psoriasis | Phase 2 | Completed | Provectus Pharmaceuticals | 30 | 2015-01-01 | 2017-11-13 |
| Randomized Study of PH-10 for Psoriasis PH-10 (0.002% Rose Bengal), PH-10 (0.005% Rose Bengal), PH-10 (0.01% Rose Bengal) - Psoriasis | Phase 2 | Completed | Provectus Pharmaceuticals | 99 | 2010-12-01 | 2012-09-28 |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver PV-10 (10% rose bengal disodium) - Cancer Metastatic to the Liver, Hepatocellular Carcinoma | Phase 1 | Unknown | Provectus Biopharmaceuticals, Inc. | 78 | 2009-10-01 | 2022-11-02 |
| An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis PH-10 (0.001% Rose Bengal) - Psoriasis | Phase 2 | Completed | Provectus Pharmaceuticals | 30 | 2009-07-01 | 2010-07-07 |
| Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma PV-10 (10% rose bengal disodium) - Melanoma | Phase 2 | Completed | Provectus Pharmaceuticals | 80 | 2007-09-01 | 2014-08-25 |
| PV-10 Chemoablation of Recurrent Breast Carcinoma PV-10 (rose bengal disodium 10%) - Breast Cancer | Phase 1 | Completed | Provectus Pharmaceuticals | 15 | 2005-10-01 | 2008-10-24 |
| Intralesional PV-10 Chemoablation of Metastatic Melanoma PV-10 (rose bengal disodium, 10%) - Melanoma | Phase 1 | Completed | Provectus Pharmaceuticals | 20 | 2005-08-01 | 2007-08-23 |
| Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors PV-10 (10% rose bengal disodium) - Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory, Approved Alternative Therapy | No longer available | Provectus Biopharmaceuticals, Inc. | 2016-07-11 |
Melanoma (4) · Psoriasis (3) · Breast Neoplasms (2) · Acanthamoeba Keratitis (1) · Carcinoid Tumor (1) · Carcinoma, Hepatocellular (1) · Cigarette Smoking (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Leukoplakia, Oral (1) · Lichen Planus, Oral (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Recurrence (1)
Provectus Pharmaceuticals (6) · Provectus Biopharmaceuticals, Inc. (3) · University of California, San Francisco (2) · King Saud University (1) · The Oxford Dental College, Hospital and Research Center, Bangalore, India (1)
United States (7) · Australia (3) · Brazil (2) · India (2) · France (1) · Germany (1) · Italy (1) · Mexico (1) · New Zealand (1) · Saudi Arabia (1)
Eric Wachter, Ph.D. (5) · Eric Wachter, PhD (2) · Jennifer Rose-Nussbaumer, MD (2) · Nicole Varnado, MPH (2) · Chris Wynne, M.D. (1) · John F Thompson, MD (1) · Sanjiv Agarwala, M.D. (1) · Thomas Lietman, MD (1) · Tom Lietman, MD (1)
PMID 39011096, PMID 39192339, PMID 41561665, PMID 42348235
UG1EY028518 (1)